AT1.AX Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: July 30, 2025
Report Source: 2025 2nd Quarter Report
Atomo Diagnostics Ltd. Stock Analysis AT1.AX
Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The firm supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The firm has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiations as well as the early detection of pregnancy. Its products include Atomo HIV Self-Test, AtomoRapid Pascal and AtomoRapid Curie, among others. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. The AtomoRapid Pascal platform offers improved performance and usability in point of care testing.
Read More Atomo Diagnostics Ltd (AT1.AX) Chart
Key Statistics of Atomo Diagnostics Ltd (AT1.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.02Volume
288.15KP/E Ratio (TTM)
-52 Week Range
Market Cap
21.63MAvg. Volume
934.00KDividend Yield
-Financial Metrics & Statements of Atomo Diagnostics Ltd (AT1.AX)
FAQ's for Atomo Diagnostics Ltd (AT1.AX)
- According to Musaffa’s Shariah screening methodology, Atomo Diagnostics Ltd (AT1.AX) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.